Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study
Conclusion: Cetuximab plus radiotherapy appears to be feasible and active in elderly patients unsuitable for cisplatin treatment. The treatment was supported by a favorable toxicity profile.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 26, 2019 Category: Cancer & Oncology Source Type: research

Essential Oils for the Treatment of Herpes Simplex Virus Infections
Infections with herpes simplex virus type (HSV)-1 and HSV-2 are distributed worldwide. Although standard therapies with acyclovir and other synthetic drugs are available, the safety and efficacy of these drugs are limited due to the development of drug resistance and adverse side effects. The literature on essential oils and isolated compounds was reviewed regarding their antiviral activities against HSV-1 and HSV-2. The present overview aims to review experimental data and clinical trials focusing on the antiviral activity of selected essential oils and isolated oil components. HSV was found to be susceptible to many esse...
Source: Chemotherapy - June 24, 2019 Category: Cancer & Oncology Source Type: research

Inhibition of Pantothenate Synthetase by Analogs of β-Alanine Precursor Ineffective as an Antibacterial Strategy
Conclusions: Upon revision of the literature, we conclude that high enzyme selectivity or external salvage mechanisms may render this strategy futile against most bacteria.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 5, 2019 Category: Cancer & Oncology Source Type: research

Pharmacokinetics of Benzylpenicillin (Penicillin G) during Prolonged Intermittent Renal Replacement Therapy
Prolonged intermittent renal replacement therapy (PIRRT) is an increasingly adopted method of renal replacement in critically ill patients. Like continuous renal replacement therapy, PIRRT can alter the pharmacokinetics (PK) of many drugs. In this setting, dosing data for antibiotics like benzylpenicillin are lacking. In order to enable clinicians to prescribe benzylpenicillin safely and effectively, knowledge of the effects of PIRRT on the plasma PK of benzylpenicillin is required. Herein, we describe the PK of benzylpenicillin in 2 critically ill patients on PIRRT for the treatment of penicillin-susceptibleStaphylococcus...
Source: Chemotherapy - June 5, 2019 Category: Cancer & Oncology Source Type: research

Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Conclusion: Combined ACT-D+MTX chemotherapy achieved overall better efficacy and showed less toxicity than ACT-D or MTX alone, and thus can be prioritized for the treatment of LR-GTN.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 4, 2019 Category: Cancer & Oncology Source Type: research

Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin ’s and Non-Hodgkin Lymphoma
Conclusions: This study suggests a possible role of pharmacological prophylaxis with OCs and GnRH analogues.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - May 22, 2019 Category: Cancer & Oncology Source Type: research

Levofloxacin for NIH Category II Chronic Bacterial Prostatitis: A Real-Life Study
Conclusion: Levofloxacin retained its therapeutic efficacy in patients assessed in a real-life setting, and high eradication rates were attained when it was administered as a single agent. A combination of an FQ with azithromycin induced a significant improvement of eradication rates. This strategy may be an interesting option in both first-referral and relapsing cases, although caution should be exercised when patients are at risk of developing arrhythmias, tendinitis, or other adverse effects.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - May 21, 2019 Category: Cancer & Oncology Source Type: research

Acknowledgement to Reviewers
Chemotherapy 2018;63:352 (Source: Chemotherapy)
Source: Chemotherapy - May 5, 2019 Category: Cancer & Oncology Source Type: research

Contents Vol. 63, 2018
Chemotherapy 2018;63:I –VI (Source: Chemotherapy)
Source: Chemotherapy - May 5, 2019 Category: Cancer & Oncology Source Type: research

< b > < i > IL1RN < /i > < /b > Polymorphisms Are Associated with a Decreased Risk of Esophageal Cancer Susceptibility in a Chinese Population
Conclusions: Our study provided the first evidence thatIL1RN rs3181052, rs452204, and rs315919 are correlated with a decreased risk of esophageal cancer in a Northwest Han Chinese population. These findings may be useful for the development of early prognostics for esophageal cancer. However, further larger studies on different ethnic populations are warranted to verify these findings.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - April 17, 2019 Category: Cancer & Oncology Source Type: research

Cancer Therapy-Related Cardiac Dysfunction: Are We Treating Echocardiograms, Patients, Neither, or Both?
Chemotherapy 2018;63:338 –339 (Source: Chemotherapy)
Source: Chemotherapy - April 15, 2019 Category: Cancer & Oncology Source Type: research

Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review
In conclusion, with the present case report, we confirm ruxolitinib efficacy in reducing bone marrow fibrosis grade and assume its possible role in the resolution of osteolytic lesions in PMF. Obviously, further studies with a greater number of patients are needed to document the exact frequency of these unusual findings and the possible role of ruxolitinib in their treatment.Chemotherapy 2018;63:340 –344 (Source: Chemotherapy)
Source: Chemotherapy - April 15, 2019 Category: Cancer & Oncology Source Type: research

Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible < b > < i > Staphylococcus aureus < /i > < /b > Bloodstream Infections
Conclusions: Among nafcillin- or cefazolin-treated patients with MSSA BSI, there was no significant difference in treatment failure. Observing more frequent presumptive adverse effects associated with nafcillin receipt, future prospective studies evaluating cefazolin appear warranted.Chemotherapy 2018;63:345 –351 (Source: Chemotherapy)
Source: Chemotherapy - April 15, 2019 Category: Cancer & Oncology Source Type: research

Comparative Emergence of Resistance to Clofoctol, Erythromycin, and Amoxicillin against Community-Acquired Bacterial Respiratory Tract Pathogens in Italy
In this study, we focused on clo ­foctol and aimed to verify the emergence of clofoctol resistance over time. Additionally, the ability of clofoctol to induce resistance under static and dynamic conditions was evaluated. The minimum inhibitory concentration (MIC) values measured in pathogens isolated from 1990 to 1995 were compare d to those isolated from 2017 to 2018. The behaviour of clofoctol is similar to that of amoxicillin, while erythromycin shows a different behaviour with an increase in MIC. A rapid decline in CFUs with complete eradication at 96 and 120 h in the case of clofoctol and amoxicillin, respectively...
Source: Chemotherapy - March 25, 2019 Category: Cancer & Oncology Source Type: research

Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor
Conclusion: IM Cmin at steady state was significantly associated with body weight and body surface area. Monitoring of IM Cmin might be particularly important for the optimal treatment with IM of male patients and those who have undergone gastrectomy.Chemotherapy 2018;63:301 –307 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

Overexpression of TEL-MN1 Fusion Enhances Resistance of HL-60 Cells to Idarubicin
Conclusion: Taken together, our results indicated that TEL-MN1 fusion is an oncogene involved in the leukemogenesis process and TEL-MN1 overexpression enhanced resistance of HL-60 cells to idarubicin, which may provide a useful tool for studying the mechanism of leukemogenesis and drug resistance.Chemotherapy 2018;63:308 –314 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction
Conclusions: The ability to improve symptoms and LVEF in unfit cancer patients makes ivabradine a reasonable pharmacological tool for treating CTrLVD.Chemotherapy 2018;63:315 –320 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

Use of Rifabutin as an Alternative Agent for Human Brucellosis: A Case Report
We present a case that developed intolerance to many anti-brucella drugs, who was then successfully treated with a combination of rifabutin, ofloxacin, and ceftriaxone.Chemotherapy 2018;63:321 –323 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

False Positive Cardiotoxicity Events in Cancer-Related Clinical Trials: Risks Related to Imperfect Noninvasive Parameters
Conclusion: A 3.60% false positive rate in trials where the expected level of toxicity is low suggests that false positives are troubling and may exceed true positive results. Strategies to reduce the number of false positive results include making confirmatory studies mandatory. Evaluating increases along with decreases obtains some estimation of variance.Chemotherapy 2018;63:324 –329 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model
Conclusions: This study showed partial efficacy of AZD3342 in reducing tumor growth and delaying the onset of severe diarrhea caused by MTX in rats. We suggest further studies be undertaken targeting appropriate scheduling of AZD3342 as well as investigating different cytotoxic therapies that strongly activate MMP signaling.Chemotherapy 2018;63:284 –292 (Source: Chemotherapy)
Source: Chemotherapy - February 7, 2019 Category: Cancer & Oncology Source Type: research

Ginsenoside-Rg5 Inhibits Retinoblastoma Proliferation and Induces Apoptosis through Suppressing BCL2 Expression
Conclusion: Ginsenoside-Rg5 inhibits cell proliferation and induces apoptosis in retinoblastoma cells by inactivating the AKT signaling pathway, thereby downregulating BCL2 expression.Chemotherapy 2018;63:293 –300 (Source: Chemotherapy)
Source: Chemotherapy - February 7, 2019 Category: Cancer & Oncology Source Type: research

Combining Tumor-Selective Bacterial Therapy with < b > < i > Salmonella typhimurium < /i > < /b > A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing ’s Sarcoma in a Patient-Derived Orthotopic Xenograft Model
Conclusions: The present results suggest that the combination ofS. typhimurium A1-R and o-rMETase has promise to be a transformative therapy for ES.Chemotherapy 2018;63:278 –283 (Source: Chemotherapy)
Source: Chemotherapy - January 27, 2019 Category: Cancer & Oncology Source Type: research

Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer
Conclusions: In this case, we described recurrence of nivolumab-induced pneumonitis as a serious adverse event in immune checkpoint inhibitors. Our case illustrates that immune-related adverse events may correlate with antitumour activity, even after treatment discontinuation. In addition, this case suggests the possible clinical utility of CEA serum levels for the assessment of (durable) effects of immunotherapy.Chemotherapy 2018;63:272 –277 (Source: Chemotherapy)
Source: Chemotherapy - December 20, 2018 Category: Cancer & Oncology Source Type: research

ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2
This study was designed to investigate the role of ZEB1 and SLC3A2 in the chemoresistance to cisplatin in ovarian cancer cells. We found that ZEB1 was increased in cisplatin-resistant SKOV3/DPP cells. Downregulation of ZEB1 significantly decreased cell viability in response to cisplatin, increased cis ­platin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. In addition, downregulation of ZEB1 decreased the volume and weight of implanted tumors. SLC3A2 was decreased in cisplatin-resistant SKOV3/DPP cells. Upregulation of SLC3A2 significantly decreased cell via bility in response to c...
Source: Chemotherapy - November 27, 2018 Category: Cancer & Oncology Source Type: research

Small-Cell Lung Cancer Comorbid with Pulmonary < b > < i > Mycobacterium avium < /i > < /b > Infection: A Case Report
Conclusions: Treatments for concurrent SCLC and pulmonary MAC infection may be successfully conducted with discontinuation of CAM and RFP before and after etoposide administration.Chemotherapy 2018;63:257 –261 (Source: Chemotherapy)
Source: Chemotherapy - November 22, 2018 Category: Cancer & Oncology Source Type: research

Isavuconazole: Case Report and Pharmacokinetic Considerations
Invasive fungal disease (IFD) is one of the major causes of morbidity and mortality in immunocompromised patients. Voriconazole (VCZ) and posaconazole (PCZ) remain the most widely used antifungals for the prophylaxis and treatment of IFD. However, VCZ and PCZ are liable for drug-drug interactions and show a pharmacokinetic variability that requires therapeutic drug monitoring (TDM). Isavuconazole (IVZ) is a newest generation triazole antifungal approved for the treatment of invasive aspergillosis (IA) in adult patients and for the treatment of invasive mucormycosis in adult patients for whom treatment with amphotericin B i...
Source: Chemotherapy - November 20, 2018 Category: Cancer & Oncology Source Type: research

Hepatitis B Reactivation Rate Is Higher Undergoing Some Cytotoxic Chemotherapy in Patients with Solid Tumors: A Large Retrospective Study
Conclusion: Increased reactivation rates were detected with usage of 5-FU, cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine.Chemotherapy 2018;63:247 –252 (Source: Chemotherapy)
Source: Chemotherapy - November 8, 2018 Category: Cancer & Oncology Source Type: research

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph ’+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
We report on a young patient affected by Ph’+-ALL, who relapsed after the second HSCT and who reached molecular remission and long-term disease control by treatment with the anti-CD22 monoclonal antibody inotuzumab ozogamicin, DLI, and the 3rd generation TKI ponatinib.Chemotherapy 2018;63:220 –224 (Source: Chemotherapy)
Source: Chemotherapy - October 29, 2018 Category: Cancer & Oncology Source Type: research

Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) continues to be a deadly disease, with only 50 –70% of patients achieving complete remission and less than 30% of adults having sustained long-term remissions. In order to address these unmet medical needs, we carried out a high-throughput screen of an in-house library of on- and off-patent drugs with the OCI/AML-2 cell line. Through this scre en, we discovered adefovir dipi­voxil (adefovir-DP) as being active against human AML. In addition to adefovir-DP, there are second-generation formulations of adefovir, including octadecyloxyethyl adefovir (ODE-adefovir) and hexadecyloxypropyl a...
Source: Chemotherapy - October 29, 2018 Category: Cancer & Oncology Source Type: research

Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen
Conclusions: A primary personalized cardioprotection strategy decreases the number of cardiac deaths and may potentially prolong overall survival in NHL patients with increased risk of anthracycline cardiotoxicity.Chemotherapy 2018;63:238 –245 (Source: Chemotherapy)
Source: Chemotherapy - October 29, 2018 Category: Cancer & Oncology Source Type: research

The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Conclusions: Endostar durative transfusion combined with chemotherapy showed a higher DCR, longer PFS and OS time, and was well tolerated in patients with advanced NSCLC.Chemotherapy 2018;63:214 –219 (Source: Chemotherapy)
Source: Chemotherapy - October 24, 2018 Category: Cancer & Oncology Source Type: research

Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy
Conclusions: A ceftolozane/tazobactam dose of 500 mg/250 mg appears to be sufficient to attain pharmacokinetic/pharmacodynamic targets during PIRRT while the manufacturer ’s recommended dosing of 100 mg/50 mg every 8 h was sufficient during non-PIRRT periods.Chemotherapy 2018;63:203 –206 (Source: Chemotherapy)
Source: Chemotherapy - October 10, 2018 Category: Cancer & Oncology Source Type: research

Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study
Conclusions: Although Hyper-CVAD and PE ­THEMA ALL-93 showed similar effects, Hyper-CVAD was tolerated better. Age and comorbidities should be taken into account before a chemotherapy regimen is determined for patients with ALL.Chemotherapy 2018;63:207 –213 (Source: Chemotherapy)
Source: Chemotherapy - October 10, 2018 Category: Cancer & Oncology Source Type: research

No Therapeutic Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Retreatment Despite T790M Disappearance: Case Report of 3 Cases
Conclusions: Responsiveness to EGFR-TKI might not be restored in some cases, although the disappearance of T790M mutations is confirmed.Chemotherapy 2018;63:198 –202 (Source: Chemotherapy)
Source: Chemotherapy - August 24, 2018 Category: Cancer & Oncology Source Type: research

< b > < i > NOS3 < /i > < /b > 895G & gt;T and < b > < i > CBR3 < /i > < /b > 730G & gt;A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP
Conclusions: Our results suggest thatNOS3 895G#x3e;T andCBR3 730G#x3e;A are genetic markers that can be used to predict tumor recurrence in NMIBC patients receiving intravesical instillations of THP. The effects of those 2 SNPs are independent of the EORTC scores. Further studies with larger sample sizes and longer follow-ups are needed to confirm our results.Chemotherapy 2018;63:191 –197 (Source: Chemotherapy)
Source: Chemotherapy - August 20, 2018 Category: Cancer & Oncology Source Type: research

< b > < i > NOS3 < /i > < /b > 895G & #3e;T and < b > < i > CBR3 < /i > < /b > 730G & #3e;A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP
Conclusions: Our results suggest thatNOS3 895G#x3e;T andCBR3 730G#x3e;A are genetic markers that can be used to predict tumor recurrence in NMIBC patients receiving intravesical instillations of THP. The effects of those 2 SNPs are independent of the EORTC scores. Further studies with larger sample sizes and longer follow-ups are needed to confirm our results.Chemotherapy 2018;63:191 –197 (Source: Chemotherapy)
Source: Chemotherapy - August 17, 2018 Category: Cancer & Oncology Source Type: research

Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive < b > < i > EGFR < /i > < /b > Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors
Conclusions: PPS has a stronger impact on OS than PFS does in elderly patients with NSCLC harboring sensitiveEGFR mutations and treated with first-line EGFR-TKI. These results indicate that OS in this patient population may be influenced by treatments subsequent to first-line chemotherapy; however, this remains to be verified in prospective studies.Chemotherapy 2018;63:181 –189 (Source: Chemotherapy)
Source: Chemotherapy - August 14, 2018 Category: Cancer & Oncology Source Type: research

Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease
The emergence and spread of drug-resistant strains ofMycobacterium tuberculosis is worsening the global threat of tuberculosis (TB). There is a need and urgency for the development of new treatments for TB, for the management of drug resistant TB (MDR-TB) and for improved regimens against drug-susceptible TB, with the goal of reducing toxicity and length of therapy that will boost patience compliance. The paucity of new drugs is a major obstacle to design new regimens while host-directed therapies (HDTs) are emerging as a promising area of research and are opening new avenues to fight TB. In this review, we discuss example...
Source: Chemotherapy - July 20, 2018 Category: Cancer & Oncology Source Type: research

Specifications of Computerized Provider Order Entry and Clinical Decision Support Systems for Cancer Patients Undergoing Chemotherapy: A Systematic Review
Conclusion: In complicated settings such as chemotherapy, simplification of the processes is more imperative. The use of chemotherapy CPOE, which includes specifications for helping the medical staff with their workload, encourages the professionals to use such systems and increases the likelihood for success of these systems.Chemotherapy 2018;63:162 –171 (Source: Chemotherapy)
Source: Chemotherapy - July 3, 2018 Category: Cancer & Oncology Source Type: research

Isoliquiritigenin Suppresses Osteosarcoma U2OS Cell Proliferation and Invasion by Regulating the PI3K/Akt Signalling Pathway
Conclusion: ISL could retard proliferation and promote apoptosis of U2OS cells possibly by suppressing the PI3K/Akt signalling pathway, indicating that it might be a potential therapeutic agent for osteosarcoma treatment.Chemotherapy 2018;63:155 –161 (Source: Chemotherapy)
Source: Chemotherapy - June 22, 2018 Category: Cancer & Oncology Source Type: research

Genetic Diversity of < b > < i > Mycobacterium tuberculosis < /i > < /b > Isolates in the Metropolitan Area of Rome
Conclusions: Dynamics of TB transmission in Rome indicate recent spread ofMtb strains belonging to phylogeographic lineages and clades usually found in countries and geographic areas with a high incidence of TB, similarly to what is observed in most metropolitan areas in Western Europe. Knowledge from molecular and classical epidemiology provides an important tool for disease control.Chemotherapy 2018;63:148 –154 (Source: Chemotherapy)
Source: Chemotherapy - June 15, 2018 Category: Cancer & Oncology Source Type: research

Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network
Conclusion: Usefulness of and satisfaction with available treatment options for PM were rated as moderate at best by oncological experts, and treatment strategies differed importantly among participants. There appears to be a clear need for standardization and new treatment modalities.Chemotherapy 2018;63:143 –147 (Source: Chemotherapy)
Source: Chemotherapy - June 13, 2018 Category: Cancer & Oncology Source Type: research

Carboplatin Dosing Accuracy by Estimation of Glomerular Filtration versus Creatinuria in Cancer Patients
Conclusions: GFR formulae and calculation of the carboplatin dose have good accuracy with the GFR obtained based on the 24-h creatinine clearance, with the Wright formula being the one with best performance and CG the one with worst performance.Chemotherapy 2018;63:137 –142 (Source: Chemotherapy)
Source: Chemotherapy - May 16, 2018 Category: Cancer & Oncology Source Type: research

Second International Colloquium on Cardio-Oncology, Krakow, May 3 - 4, 2018
Chemotherapy 2018;63:111 –111 (Source: Chemotherapy)
Source: Chemotherapy - April 26, 2018 Category: Cancer & Oncology Source Type: research

Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox
Iron overload (IOL) due to transfusion-dependent anemia is a serious adverse effect in patients with myelofibrosis (MF). Recent studies have shown that the oral iron chelator deferasirox may prevent multiple organ damage due to IOL in MF. However, it is not clear whether deferasirox may contribute to revert transfusion-dependent anemia. Here, we present a patient with transfusion-dependent intermediate-2 MF according to the International Prognostic Scoring System treated with ruxolitinib in combination with deferasirox. In addition to a reduced serum ferritin level, the patient required less blood transfusions, ultimately ...
Source: Chemotherapy - April 25, 2018 Category: Cancer & Oncology Source Type: research

Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia
Conclusion: Increasing age, higher MTX dose per BSA, lower baseline serum protein, and first HDMTX course were significant risk factors for developing HDMTX-induced AKI in childhood ALL. The threshold of 48-h MTX plasma concentration is valuable for the prediction of HDMTX-induced AKI.Chemotherapy 2018;63:101 –107 (Source: Chemotherapy)
Source: Chemotherapy - April 19, 2018 Category: Cancer & Oncology Source Type: research

In vitro Antichlamydial Activity of 1,2,3,5-Tetrasubstituted Pyrrole Derivatives
Conclusion: Our findings highlight the potential of 1,2,3,5-tetrasubstituted pyrrole derivatives as promising lead molecules for the development of antichlamydial agents.Chemotherapy 2018;63:96 –100 (Source: Chemotherapy)
Source: Chemotherapy - April 12, 2018 Category: Cancer & Oncology Source Type: research

Erratum
Chemotherapy 2018;63:64 –64 (Source: Chemotherapy)
Source: Chemotherapy - April 10, 2018 Category: Cancer & Oncology Source Type: research

A Complete Pathological Response to Pembrolizumab following ex vivo Liver Resection in a Patient with Colorectal Liver Metastases
Advances in the systemic treatment of stage IV colorectal cancer with liver metastases has offered improved survival rates for patients who otherwise face a dismal prognosis. However, a pathologically complete response (PCR) to chemotherapy for colorectal liver metastases is still rare, and its significance is not fully understood. In this case report, we describe a patient who achieved PCR after neoadjuvant immunotherapy with pembrolizumab and a left hepatectomy using an ex vivo resection technique.Chemotherapy 2018;63:90 –94 (Source: Chemotherapy)
Source: Chemotherapy - April 5, 2018 Category: Cancer & Oncology Source Type: research